NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer
Latest Information Update: 28 Sep 2023
At a glance
- Drugs Atezolizumab (Primary) ; Carboplatin; Cisplatin; Etoposide; Paclitaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms NASSIST
- 22 Sep 2023 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 22 Sep 2023 Planned initiation date changed from 10 Sep 2021 to 9 Sep 2021.
- 03 Mar 2023 Status changed from recruiting to active, no longer recruiting.